Technical Data
ISG15, ID (R87) (Interferon-induced 17kD Protein, Ubiquitin Cross-reactive Protein, hUCRP, Interferon-induced 15kD Protein,G1P2, UCRP, Ubiquitin-like Protein ISG15, IP17)
ISG15 is secreted from monocytes in response to type I interferons and causes natural killer (NK)-cell proliferation and an augmentation of non-MCH (major histocompatibility complex)-restricted cytotoxicity. Synthesis is stimulated by IFN-alpha or IFN-beta or IFN-omega , but not IFN-gamma . ISG15 expression is also induced by overexpression of interferon regulatory factors that participate in transcriptional regulation of IFN genes, and by influenza B virus. ISG15 is secreted also by cell lines of monocyte, T-lymphocyte, B-lymphocyte, human fibroblasts, and epithelial origins. The induction of terminal differentiation in human melanoma cells is associated with alterations in ISG15 expression. Enhancement of NK cell proliferation, augmentation of non-major histocompatibility complex-restricted cytotoxicity, and induction of IFN-gamma from T cells identify ISG15 as a member of the cytokine cascade and suggest that it may be responsible for amplifying and directing some of the immunomodulatory effects of IFN-alpha or IFN-beta. ISG15 has has also been shown to function intracellularly as a ubiquitin homolog.

Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 1:1,000
Western Blot: 1:50-1:100
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
200ul-20CBlue IceHumanRabbit
As reported
Synthetic peptide selected from the Center region of human ISG15 (KLH).
Purified by ammonium sulfate precipitation.
Supplied as a liquid in PBS, 0.09% sodium azide.
Recognizes human ISG15.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1.Padovan, E., et al., Cancer Res. 62(12):3453-3458 (2002). 2.Meraro, D., et al., J. Immunol. 168(12):6224-6231 (2002). 3.Reich, N., et al., Proc. Natl. Acad. Sci. USA 84(18):6394-6398 (1987). 4.Blomstrom, D.C., et al., J. Biol. Chem. 261(19):8811-8816 (1986). 5.Clauss, I.M., et al., Cytogenet. Cell Genet. 53(2-3), 166-168 (1990).